Eliem Therapeutics CSO departs, CFO role changed, Executive Chairman resigns amid strategic pivot

Climb Bio, Inc.

Valerie Morisset, EVP R&D and CSO, separated August 23; settlement provides 18 months base salary, pro rata bonus, accelerated equity vesting.
Company shifts focus to autoimmune-driven inflammatory diseases (budoprutug) and ceases UK operations.
Brett Kaplan appointed principal financial officer after Andrew Levin resigns as Executive Chairman; Levin remains Chairman.
Levin continues as director and Chairman of Board; Kaplan's COO role unchanged.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brett Kaplan

principal financial officer

CLYM · Climb Bio, Inc.

Effective: 2024-08-26
Filed: August 27, 2024, 7:59 PM ET

On August 26, 2024, the Board of Directors of the Company (the “Board”) appointed Brett Kaplan, the Company’s Chief Operating Officer, to serve as principal financial officer.

Role change

Andrew Levin

Chairman of the Board

CLYM · Climb Bio, Inc.

Effective: 2024-08-26
Filed: August 27, 2024, 7:59 PM ET

The appointment was made in connection with Andrew Levin’s resignation from his role as Executive Chairman of the Company. Dr. Levin continues to serve as a director of the Company and was appointed Chairman of the Board in connection with his resignation as Executive Chairman.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brett Kaplan was appointed as principal financial officer at Climb Bio, Inc..

Action: appointed
Role: principal financial officer

Exact text from the filing

On August 26, 2024, the Board of Directors of the Company (the “Board”) appointed Brett Kaplan, the Company’s Chief Operating Officer, to serve as principal financial officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Levin was appointed as Chairman of the Board at Climb Bio, Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

The appointment was made in connection with Andrew Levin’s resignation from his role as Executive Chairman of the Company. Dr. Levin continues to serve as a director of the Company and was appointed Chairman of the Board in connection with his resignation as Executive Chairman.

View on SEC.gov

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-207854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.